Jong Kim1, Christopher Bell1, Maggie Sun1, Gordon Kliewer1, Linan Xu1, Maria McInerney1, Lawrence W Svenson1, Huiming Yang2. 1. Public Health and Preventive Medicine Residency Program (Kim), Cumming School of Medicine, University of Calgary, Calgary; Surveillance and Assessment Branch (Bell, Svenson), Alberta Health, Edmonton; Screening Programs (Sun, Kliewer, Xu, McInerney, Yang), Alberta Health Services, Calgary; School of Public Health (Svenson), University of Alberta, Edmonton; Department of Community Health Sciences (Svenson), Cumming School of Medicine, University of Calgary, Alta. 2. Public Health and Preventive Medicine Residency Program (Kim), Cumming School of Medicine, University of Calgary, Calgary; Surveillance and Assessment Branch (Bell, Svenson), Alberta Health, Edmonton; Screening Programs (Sun, Kliewer, Xu, McInerney, Yang), Alberta Health Services, Calgary; School of Public Health (Svenson), University of Alberta, Edmonton; Department of Community Health Sciences (Svenson), Cumming School of Medicine, University of Calgary, Alta. Huiming.Yang@albertahealthservices.ca.
Abstract
BACKGROUND: A school-based program with quadrivalent human papillomavirus (HPV) vaccination was implemented in Alberta in 2008. We assessed the impact of this program on Pap test cytology results using databases of province-wide vaccination and cervical cancer screening. METHODS: We conducted a nested case-control study involving a cohort of women in Alberta born between 1994 and 1997 who had at least 1 Pap test between 2012 and 2015. Women with negative cytology results were controls. Women with low-grade (atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion) and high-grade (atypical squamous cells, cannot rule out a high-grade lesion; or high-grade squamous intraepithelial lesion) cervical abnormalities were cases. Exposure status was assigned according to records of HPV vaccination. Odds ratios (ORs) for abnormal cytology results by vaccination status were adjusted for neighbourhood income, laboratory service, rural versus urban residency, and age. RESULTS: The total study population was 10 204. Adjusting for age, vaccinated women had a higher screening rate than unvaccinated women (13.0% v. 11.4%, p < 0.001). Among women who received full vaccination (≥ 3 doses), the adjusted OR for cervical abnormalities was 0.72 (95% confidence interval [CI] 0.63-0.82). For high-grade lesions, the adjusted OR was 0.50 (95% CI 0.30-0.85). With 2-dose HPV vaccination, the adjusted OR for cervical abnormalities was 1.08 (95% CI 0.84-1.38). INTERPRETATION: Quadrivalent HPV vaccination significantly reduced high-grade cervical abnormalities but required 3 doses. Vaccination against HPV was associated with screening uptake. Population-based vaccination and screening programs should work together to optimize cervical cancer prevention.
BACKGROUND: A school-based program with quadrivalent human papillomavirus (HPV) vaccination was implemented in Alberta in 2008. We assessed the impact of this program on Pap test cytology results using databases of province-wide vaccination and cervical cancer screening. METHODS: We conducted a nested case-control study involving a cohort of women in Alberta born between 1994 and 1997 who had at least 1 Pap test between 2012 and 2015. Women with negative cytology results were controls. Women with low-grade (atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion) and high-grade (atypical squamous cells, cannot rule out a high-grade lesion; or high-grade squamous intraepithelial lesion) cervical abnormalities were cases. Exposure status was assigned according to records of HPV vaccination. Odds ratios (ORs) for abnormal cytology results by vaccination status were adjusted for neighbourhood income, laboratory service, rural versus urban residency, and age. RESULTS: The total study population was 10 204. Adjusting for age, vaccinated women had a higher screening rate than unvaccinated women (13.0% v. 11.4%, p < 0.001). Among women who received full vaccination (≥ 3 doses), the adjusted OR for cervical abnormalities was 0.72 (95% confidence interval [CI] 0.63-0.82). For high-grade lesions, the adjusted OR was 0.50 (95% CI 0.30-0.85). With 2-dose HPV vaccination, the adjusted OR for cervical abnormalities was 1.08 (95% CI 0.84-1.38). INTERPRETATION: Quadrivalent HPV vaccination significantly reduced high-grade cervical abnormalities but required 3 doses. Vaccination against HPV was associated with screening uptake. Population-based vaccination and screening programs should work together to optimize cervical cancer prevention.
Authors: K Nanda; D C McCrory; E R Myers; L A Bastian; V Hasselblad; J D Hickey; D B Matchar Journal: Ann Intern Med Date: 2000-05-16 Impact factor: 25.391
Authors: Leah M Smith; Erin C Strumpf; Jay S Kaufman; Aisha Lofters; Michael Schwandt; Linda E Lévesque Journal: Pediatrics Date: 2015-05 Impact factor: 7.124
Authors: Julia M L Brotherton; Masha Fridman; Cathryn L May; Genevieve Chappell; A Marion Saville; Dorota M Gertig Journal: Lancet Date: 2011-06-18 Impact factor: 79.321
Authors: Susan Hariri; Michelle L Johnson; Nancy M Bennett; Heidi M Bauer; Ina U Park; Sean Schafer; Linda M Niccolai; Elizabeth R Unger; Lauri E Markowitz Journal: Cancer Date: 2015-06-22 Impact factor: 6.860
Authors: Kevin A Ault; Elmar A Joura; Susanne K Kjaer; Ole-Erik Iversen; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Suzanne M Garland; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Marc Steben; F Xavier Bosch; Slawomir Majewski; Nubia Muñoz; Heather L Sings; Kathy Harkins; Mary Anne Rutkowski; Richard M Haupt; Elizabeth I O Garner Journal: Int J Cancer Date: 2011-01-12 Impact factor: 7.396
Authors: Beatriz Serrano; Laia Alemany; Sara Tous; Laia Bruni; Gary M Clifford; Thomas Weiss; Francesc Xavier Bosch; Silvia de Sanjosé Journal: Infect Agent Cancer Date: 2012-12-29 Impact factor: 2.965
Authors: Xianfang C Liu; Christopher A Bell; Kimberley A Simmonds; Margaret L Russell; Lawrence W Svenson Journal: BMC Infect Dis Date: 2016-01-13 Impact factor: 3.090
Authors: Elizabeth Crowe; Nirmala Pandeya; Julia M L Brotherton; Annette J Dobson; Stephen Kisely; Stephen B Lambert; David C Whiteman Journal: BMJ Date: 2014-03-04
Authors: Michael J Silverberg; Wendy A Leyden; Jennifer O Lam; Steven E Gregorich; Megan J Huchko; Shalini Kulasingam; Miriam Kuppermann; Karen K Smith-McCune; George F Sawaya Journal: Lancet Child Adolesc Health Date: 2018-08-08
Authors: Michelle L Johnson Jones; Julia Warner Gargano; Melissa Powell; Ina U Park; Linda M Niccolai; Nancy M Bennett; Marie R Griffin; Troy Querec; Elizabeth R Unger; Lauri E Markowitz Journal: Am J Epidemiol Date: 2020-04-02 Impact factor: 4.897